Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M P Ebert

Showing results (1-10 of 31) with videos related to

Pageof 4
Sort By:
Zeitschrift Fur Gastroenterologie|February 22, 2002
[Early gastrectomy in young, asymptomatic carriers of E-cadherin germline mutations]M P Ebert, H Friess
Digestive Diseases (Basel, Switzerland)|December 15, 2005
Interventional endoscopy and laparoscopy in GI diseasesM P Ebert, P Malfertheiner
Deutsche Medizinische Wochenschrift (1946)|September 4, 2009
[The neoadjuvant treatment of gastrointestinal tumors: time for rethinking?]M P Ebert, R M Schmid
Hepato-Gastroenterology|January 30, 2002
Novel strategies in the prevention of gastric cancerM P Ebert, A Leodolter, P Malfertheiner
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|March 14, 2001
Cadherins and catenins in inflammation and oncogenesisL Schandl, M P Ebert, P Malfertheiner
Zeitschrift Fur Gastroenterologie|September 12, 2012
Treatment of hepatocellular carcinoma with sorafenib - focus on special populations and adverse event managementE Schott, M P Ebert, J Trojan
Histology and Histopathology|February 10, 2007
Anti-lambda-light chain-peptide antibodies are suitable for the immunohistochemical classification of AL amyloidH Kuçi, M P Ebert, C Röcken
European Journal of Gastroenterology & Hepatology|August 10, 2000
Molecular alterations in gastric cancer: the role of Helicobacter pyloriM P Ebert, J Yu, J J Sung, et al.
British Journal of Cancer|February 16, 2013
Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancerV Heinemann, M P Ebert, R P Laubender, et al.
European Journal of Gastroenterology & Hepatology|July 4, 2001
Validity of a Helicobacter pylori stool antigen assay for the assessment of H. pylori status following eradication therapyA Leodolter, K Agha-Amiri, U Peitz, et al.
Pageof 4

Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
Zeitschrift Fur Gastroenterologie|February 22, 2002
[Early gastrectomy in young, asymptomatic carriers of E-cadherin germline mutations]M P Ebert, H Friess
Digestive Diseases (Basel, Switzerland)|December 15, 2005
Interventional endoscopy and laparoscopy in GI diseasesM P Ebert, P Malfertheiner
Deutsche Medizinische Wochenschrift (1946)|September 4, 2009
[The neoadjuvant treatment of gastrointestinal tumors: time for rethinking?]M P Ebert, R M Schmid
Hepato-Gastroenterology|January 30, 2002
Novel strategies in the prevention of gastric cancerM P Ebert, A Leodolter, P Malfertheiner
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|March 14, 2001
Cadherins and catenins in inflammation and oncogenesisL Schandl, M P Ebert, P Malfertheiner
Zeitschrift Fur Gastroenterologie|September 12, 2012
Treatment of hepatocellular carcinoma with sorafenib - focus on special populations and adverse event managementE Schott, M P Ebert, J Trojan
Histology and Histopathology|February 10, 2007
Anti-lambda-light chain-peptide antibodies are suitable for the immunohistochemical classification of AL amyloidH Kuçi, M P Ebert, C Röcken
European Journal of Gastroenterology & Hepatology|August 10, 2000
Molecular alterations in gastric cancer: the role of Helicobacter pyloriM P Ebert, J Yu, J J Sung, et al.
British Journal of Cancer|February 16, 2013
Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancerV Heinemann, M P Ebert, R P Laubender, et al.
European Journal of Gastroenterology & Hepatology|July 4, 2001
Validity of a Helicobacter pylori stool antigen assay for the assessment of H. pylori status following eradication therapyA Leodolter, K Agha-Amiri, U Peitz, et al.
Pageof 4